IL1A and Parkinson disease: NLY01, used to block the induction of inflammatory astrocytes by inhibiting the release of IL-1α, TNF-α and C1q from microglia, was successfully used in studies of PD (Yun et al., 2018) and glaucoma-associated neurodegeneration (Sterling et al., 2020) to ameliorate disease severity.